Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

2001 • 16,438 citations

ras oncogenes in human cancer: a review.

1989 • 5,116 citations

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

2004 • 3,873 citations

Targeting RAS signalling pathways in cancer therapy

2003 • 3,105 citations

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

2004 • 2,674 citations

Tumor Suppressor Genes

1991 • 1,784 citations

CELLULAR ONCOGENES AND RETROVIRUSES

1983 • 1,671 citations

Mechanism of activation of a human oncogene

1982 • 1,417 citations

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

2002 • 1,349 citations

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1984 • 1,153 citations

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

2006 • 1,030 citations

BRAF and RAS mutations in human lung cancer and melanoma.

2002 • 979 citations

Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene

1982 • 928 citations

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

2002 • 925 citations

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

2004 • 855 citations

Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma

2004 • 778 citations

c-Src and cooperating partners in human cancer

2004 • 586 citations

The Fos family of transcription factors and their role in tumourigenesis

2005 • 550 citations

Retroviruses

1988 • 512 citations

Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus

1986 • 478 citations

BAY 43-9006 Inhibition of Oncogenic RET Mutants

2006 • 466 citations

Silencing of Epidermal Growth Factor Receptor Suppresses Hypoxia-Inducible Factor-2–Driven VHL−/− Renal Cancer

2005 • 459 citations

Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study

2005 • 435 citations

Discovery of a novel Raf kinase inhibitor.

2001 • 417 citations

Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis

1994 • 354 citations

Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors

2005 • 335 citations

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

2005 • 328 citations

Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors

2005 • 316 citations

Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1

2004 • 314 citations

Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib

2005 • 310 citations

Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma.

1995 • 304 citations

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

2016 • 304 citations

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

2005 • 298 citations

Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation

2005 • 281 citations

Analysis of BRAF Point Mutation and RET/PTC Rearrangement Refines the Fine-Needle Aspiration Diagnosis of Papillary Thyroid Carcinoma

2004 • 272 citations

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006

2005 • 272 citations

The KRAS oncogene: Past, present, and future

2005 • 256 citations

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

2005 • 230 citations

Retroviruses as etiologic agents of some animal and human leukemias and lymphomas and as tools for elucidating the molecular mechanism of leukemogenesis

1982 • 210 citations

Erlotinib hydrochloride

2005 • 204 citations

Epidermal growth factor and its receptor

1987 • 197 citations

Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells

2003 • 187 citations

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

2006 • 187 citations

BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma

2006 • 171 citations

The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells

2006 • 170 citations

Cancer therapeutics: Targeting the dark side of Myc

2005 • 168 citations

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

2006 • 149 citations

Design and Discovery of Small Molecules Targeting Raf-1 Kinase

2002 • 146 citations

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

2006 • 143 citations

Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma

2006 • 141 citations

The Molecular Basis of Oncogenes and Tumor Suppressor Genes

1995 • 140 citations

Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma*1

2004 • 130 citations

The RET proto‐oncogene: A molecular therapeutic target in thyroid cancer

2005 • 120 citations

High Frequency of Submicroscopic Hemizygous Deletion Is a Major Mechanism of Loss of Expression ofPTENin Uveal Melanoma

2005 • 117 citations

Results of a Phase I Trial of Sorafenib (BAY 43-9006) in Combination with Oxaliplatin in Patients with Refractory Solid Tumors, Including Colorectal Cancer

2005 • 116 citations

Uninfected avian cells contain RNA related to the transforming gene of avian sarcoma viruses

1978 • 114 citations

Clinical trials referral resource.

1990 • 96 citations

The role of Raf kinases in malignant transformation

2002 • 90 citations

On a possible epigenetic mechanism(s) of tumor cell heterogeneity

1983 • 87 citations

Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach

2001 • 84 citations

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer

2001 • 71 citations

FLT-3: a new focus in the understanding of acute leukemia

2005 • 69 citations

A Scintillation Proximity Assay for the Raf/MEK/ERK Kinase Cascade: High-Throughput Screening and Identification of Selective Enzyme Inhibitors

1999 • 68 citations

Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43–9006 alone in patients with metastatic melanoma

2005 • 50 citations

RAF antisense oligonucleotide as a tumor radiosensitizer

2003 • 50 citations

Phase I trial of BAY 43–9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients

2005 • 50 citations

A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts)

2006 • 49 citations

Imatinib resistance in gastrointestinal stromal tumors

2005 • 46 citations

Raf-1 expression may influence progression to androgen insensitive prostate cancer

2005 • 45 citations

Deregulated Repression of c-Jun Provides a Potential Link to its Role in Tumorigenesis

2004 • 44 citations

Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab

2006 • 42 citations

Antisera to a synthetic peptide of the sis viral oncogene product recognize human platelet-derived growth factor

1984 • 40 citations

Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43–9006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study

2006 • 30 citations

Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006)

2006 • 27 citations

Oncogenes as Novel Targets for Cancer Therapy (Part I)

2005 • 24 citations

Bony metastatic disease responses to sorafenib (BAY 43–9006) independent of PSA in patients with metastatic androgen independent prostate cancer

2006 • 22 citations

Sensitivity of NSCLC cell lines bearing wild type and mutated EGFR to the VEGF/EGFR inhibitor ZD6474

2005 • 22 citations

Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients

2006 • 21 citations

Oncogenes as Novel Targets for Cancer Therapy (Part IV)

2005 • 19 citations

BAY 43–9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane

2006 • 16 citations

Phase I study of BAY 43–9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors

2005 • 15 citations

C-kit as a target in the treatment of acute myelogenous leukemia.

2005 • 14 citations

Phase II study of Sorafenib (BAY 43–9006) in hormone-refractory patients with prostate cancer: A study of the Central European Society for Anticancer Drug Research—EWIV (CESAR)

2006 • 12 citations

Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1.

2005 • 11 citations

A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors

2004 • 5 citations